Zhitong Finance App News, Huabei Pharmaceutical (600812.SH) issued an announcement. Recently, the company received the “Notice of Approval of Application for the Marketing of Chemical Ingredients” for cephalazine approved and issued by the State Drug Administration. Cefradine is an oral cephalosporin antibiotic. Its oral formulation targets respiratory infections such as acute pharyngitis, tonsillitis, otitis media, bronchitis, and mild pneumonia caused by sensitive bacteria, and can also be used for common mild to moderate bacterial infections of the genitourinary tract and soft tissue of the skin.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.